Health Care • Other Pharmaceuticals
$251.09 ▲ +6.33
(+2.59%)
MKT CAP: $58.14B • VOL: 1.74M
52W L $180 52W H $260
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$211
MEDIAN
$281
MEAN
$286
HIGH
$341
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE CAH TAPE
CAH // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $303.82 | $288.75 | 2025-02-14 | $228.49 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $316.37 | $296.29 | 2025-02-06 | $236.02 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $286.24 | $276.20 | 2025-01-29 | $241.05 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $256.11 | — | 2025-01-17 | $246.07 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $220.96 | $238.54 | 2025-01-09 | $223.47 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $298.80 | $261.13 | 2024-12-18 | $218.45 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $243.56 | $253.60 | 2024-12-04 | $233.51 | -4.3% | 48% | C |